Following on from information provided to NICE by the company in August 2022 the appraisal of Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process STA Standard
ID number 1538

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
29 August 2023 Discontinued. Following on from information provided to NICE by the company in August 2022 the appraisal of Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer [ID1538] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
05 August 2022 Suspended. As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Durvalumab with tremelimumab for untreated EGFR- and ALK-negative locally advanced and metastatic non-small-cell lung cancer. For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes.
16 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
24 April 2018 In progress. Topic referred

For further information on our processes and methods, please see our CHTE processes and methods manual